Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Landos Biopharma

AbbVie said on Monday it would acquire drug developer Landos Biopharma for up to $212 million as the Humira-maker aims to expand its pipeline of medicines to treat immune system-related illnesses.

AbbVie to buy Landos to expand pipeline of immunity-related illnesses

Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

Aldeyra Therapeutics

Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiered double-digit royalties for ex-US. $142M in cash at 12/31/23, burning $40M per year - plenty of cash to achieve monetization of reproxalap.

Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie

The Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen's cancer drug mirvetuximab-soravtansine-gynx, or Elahere, part of a new class of cancer treatments considered “biological missiles” because of their ability to precisely home in on cancer cells.

AbbVie's New ‘Biological Missile' Ovarian Cancer Treatment Gets Full FDA Approval

-       The full approval of ELAHERE is based on the confirmatory MIRASOL Phase 3 trial that supports the medicine as a potential new standard of care for folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer (PROC) -       Data show that ELAHERE treatment resulted in an overall survival benefit and reduced the risk of cancer progression by 35% -       ELAHERE represents AbbVie's first approved solid tumor treatment following the recent acquisition of ImmunoGen NORTH CHICAGO, Ill. , March 22, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies.

U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

The U.S. Food and Drug Administration (FDA) said on Friday it had granted traditional approval for AbbVie's "guided missile" cancer therapy, Elahere, for adult patients with a type of ovarian and related cancers who have received one to three prior lines of treatment.

US FDA grants full approval to AbbVie's ovarian cancer therapy

Agilent Technologies

Apple

Accenture Plc

Automatic Data Processing

Amgen

Amazon

Air Products and Chemicals

Ares Capital

Alexandria Real Estate Equities

ASML Hld

AvalonBay Communities

Broadcom

Booz Allen Hamilton Hld

Brookfield Asset Management

Brookfield Renewable Partners

SPDR Bloomberg 1-3 Month T-Bill ETF

Brookfield Infrastructure

Booking Hlds

Blackrock Inc

Broadridge Financial

British American Tobacco

Blackstone Group

Carrier Global

CME Group

I have been actively reshaping my portfolio by selling off low-conviction holdings and focusing on high-growth compounders. I have reduced my holdings from roughly 90 to roughly 70 over the past 6 months or so. I am excited about my current allocations and believe my portfolio changes will set them up for continued double-digit annual income growth.

More Big Changes To My Dividend Growth Portfolio

Gilead Sciences

AbbVie and Gilead Sciences haven't been recording excellent financial results lately. But both drugmakers have solid lineups and pipelines that should allow them to recover.

2 Top Dividend Stocks to Buy Hand Over Fist

AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript)

In the latest trading session, AbbVie (ABBV) closed at $179.86, marking a -0.59% move from the previous day.

Why AbbVie (ABBV) Dipped More Than Broader Market Today

AGNC Investment

Antero Midstream Partners

Apple Hospitality REIT

Apollo Commercial Real Estate Finance

Boeing

Alibaba

Bank of America

BASF SE

B&G Foods

Bank of Montreal

Bayerische Motoren Werke AG

Bank of Nova Scotia

BRT Apartments

Blackstone Secured Lending Fund

Colgate-Palmolive

Canadian Imperial Bank of Commerce

US stocks climbed higher in February with the DJIA adding 0.4% and the S&P closing in on the 5,000-point mark.

February's Dividend Portfolio Update Sets New Record - 100 Holdings, 19 Strategic Buys

Johnson & Johnson

Procter & Gamble

In investing, where uncertainty often reigns high, dividend kings are the beacons of income stability and growth. Among them, three companies hold enduring leads.

3 Must-Have Dividend Kings for a Steady Income Stream

McDonald's

Realty Income Corp

PepsiCo

Target

Exxon Mobil

At first glance, another gangbusters jobs report seems to imply that dividend stocks are irrelevant. It's all about growth, baby!

Trouble-Proof Dividend Darlings: 7 Stocks That Keep Paying No Matter What

MoonLake Immunotherapeutics

Biotech stock MoonLake popped Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira.

MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test

Ginkgo Bioworks Holdings

Pfizer

Pfizer is a rebound candidate that pays a hefty dividend while you wait. AbbVie has been broadening its product offerings to become more diversified.

3 Pharmaceutical Stocks to Buy Hand Over Fist in March

AbbVie's full-year results for 2023 might have been weak, but its price is still up by 15% YTD. The disconnect is explained by the revenue dip because of patent expiration for its blockbuster drug Humira, though revenues-ex Humira saw healthy growth. The company's other immunology drugs are promising, as is its neuroscience segment, which augur well for 2024 and beyond. Its EPS can see an uptick too.

AbbVie: Comeback Expected After Humira Patent Expiration

Salesforce

NVIDIA

Last year emerged as a time of unexpected resilience and expansion for the stock market driven by the strength of unstoppable mega-cap stocks. Notably, the S&P 500 wrapped up last year with a solid 24% gain, turning heads in the process.

3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024

Merck

Both of these healthcare giants are leaders in their industries and faithful dividend payers. AbbVie is dealing with short-term challenges, but the strength of its underlying business remains intact.

Have $2,500? 2 Superior Growth Stocks to Buy in 2024

News for AbbVie Stock (ABBV)